General AML

Andrew Wei | EHA 2018 | Targeting apoptosis in AML

L:

At the 23rd Congress of the European Hematology Association, Andrew Wei (chair of our Rest of the World steering committee) from Monash University, Melbourne, AU, discusses BCL2 inhibition which has become a promising therapeutic target in acute myeloid leukemia (AML). He further discussed an investigator-initiated phase Ib dose escalation study of venetoclax in combination with intensive chemotherapy in fit elderly AML patients.

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF